Navigation Links
Cellectar Expands Clinical Management Team
Date:10/3/2007

- Appoints Director, Clinical Operations and Manager, Medical Affairs -

MADISON, Wis., Oct. 3 /PRNewswire/ -- Cellectar LLC, (Cellectar), a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Ernest Allen as Director, Clinical Operations and LisaAnn Trembath as Manager of Medical Affairs. These appointments reflect the advancement of the company's lead product, CLR1404, toward clinical trials.

Prior to joining Cellectar, Mr. Allen spent over 20 years in progressively senior positions in clinical operations for pharmaceutical companies including Alcon, Amgen, Parke-Davis and Origin Pharmaceuticals, Inc., a U.K.-based Clinical Research Organization (CRO), where he served as Senior Clinical Manager. Most recently, he was Clinical Manager for Tapestry Pharmaceuticals, Inc., a cancer treatment pharmaceutical company located in Boulder, CO.

Ms. Trembath brings 21 years of experience as a nuclear medicine technologist specializing in medical imaging, including 10 years of clinical trials research experience and nine years in the radiopharmaceuticals industry. Immediately prior to joining Cellectar, Ms. Trembath was a Senior Clinical Affairs Specialist in the Medical Affairs Division at Bristol-Myers Squibb Medical Imaging, where she developed tools and educational programs for partner clinicians and field personnel. Prior to her position at BMS, she coordinated clinical trials research at the Medical College of Wisconsin and project management at Affiliated Research Centers.

Bill Clarke, M.D., Cellectar's President and CEO, commented, "As we advance our lead product candidate, CLR1404, toward clinical trials, Ernest and LisaAnn bring the necessary clinical development skills needed for our progression. These highly experienced individuals are excellent additions to our team."

CLR1404 is currently in preclinical development and the company expects to initiate Phase I clinical trails in mid-2008.

About Cellectar

Cellectar LLC is a radiopharmaceuticals company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells. Cellectar's products' unique mechanism of action is based on their selective accumulation and retention in malignant tumors and not normal cells. The company's operations are based in Madison, WI. Cellectar has previously raised approximately $9.0 million from angel investors; including Continuum Investment Partners. For further information about Cellectar, visit the company website at http://www.cellectar.com.

About CLR1404

Cellectar's lead product candidate, CLR1404, is a phospholipid ether (PLE) combined with the radiolabel 131Iodine. Preclinical studies have shown that this compound is selectively retained in malignant cells. In pre-clinical studies, CLR1404 was taken up and retained in 100% of the 40+ malignant tumor types tested. Cellectar plans to move the compound into phase I clinical trials in mid-2008.


'/>"/>
SOURCE Cellectar LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... SAN FRANCISCO , May 27, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, Neurology and ... Commissiong will be presenting at two upcoming investor conferences: ... Conference Center, 730 Third Avenue, New York City ... at 3:00pm Marcum MicroCap Conference   ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
(Date:5/27/2016)... ... 27, 2016 , ... Each year Standard Process Inc. ... is this year’s Life University winner of a $2,500 scholarship from ... Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life University ...
(Date:5/26/2016)... New Hampshire (PRWEB) , ... May 26, 2016 , ... ... skin care products, has been honored with a 2016 When Work Works Award for ... prestigious award, part of the national When Work Works project administered by the Families ...
(Date:5/26/2016)... ... 26, 2016 , ... Connor Sports, through its Connor Cares initiative, ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame ... in all forms and levels of the game, Connor Sports has committed to a ...
(Date:5/26/2016)... ... , ... There are nearly 14.5 million people living with and beyond cancer ... June 5, 2016, communities around the world will gather to recognize these cancer survivors ... Survivors Day® is an annual worldwide Celebration of Life that is held on the ...
Breaking Medicine News(10 mins):